See What HealthDay Can Do For You
Contact Us

Genetic Variation Impacts Pharmacokinetics of Exemestane

Significant differences in plasma exemestane area under the curve for OATP1B1 genotype groups

pills

THURSDAY, Aug. 3, 2017 (HealthDay News) -- The OATP1B1 c.521>C single nucleotide polymorphism (SNP) influences exemestane pharmacokinetics in healthy postmenopausal women, according to a study published online July 29 in the Journal of Clinical Pharmacy and Therapeutics.

B.J. Gregory, Pharm.D., from the Harding University College of Pharmacy in Searcy, Ark., and colleagues conducted a retrospective pharmacogenetic study to examine the impact of the OATP1B1 c.521T>C SNP (rs4149056) on the pharmacokinetics of exemestane in healthy volunteers. Exemestane was administered orally to 14 healthy postmenopausal women; they were all sampled for pharmacokinetic analyses and genotyped retrospectively.

The researchers found that five of the subjects were carriers of the minor C allele (OATP1B1 c.521TC+ CC) and nine were carriers of OATP1B1 c.521TT genotype. Over eight-hours post-dosing, pharmacokinetics were analyzed. The OATP1B1 genotype groups had statistically significant differences in the plasma exemestane area under the curve (AUC0-8) (P = 0.04). Statistically significant differences were also seen in the plasma AUC0-8 of 17-hydroexemestane between the OATP1B1 genotype groups (P = 0.04).

"Our data suggest that the OATP1B1 c.521T>C SNP may influence exemestane pharmacokinetics in humans," the authors write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.